BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023
31 Julho 2023 - 8:00AM
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical
company utilizing artificial intelligence approaches to develop
transformative medicines in neuroscience and immuno-oncology, today
announced that it will release its second quarter 2023 financial
results on Monday, August 14, 2023 before the open of the U.S.
financial markets. BioXcel Therapeutics’ management team will also
host a conference call and webcast at 8:00 AM ET that day to
discuss the Company’s financial results and to provide a general
business update.
Conference
Call & Webcast Details |
|
|
Date/Time: |
Monday, August 14, 2023 at
8:00 AM Eastern Time |
Domestic: |
877-407-5795 |
International: |
201-689-8722 |
The webcast and the accompanying materials will be accessible*
under "News/Events" on the Investors & Media page of the
Company's website at www.bioxceltherapeutics.com.
Replay |
|
Domestic: |
877-660-6853 |
International: |
201-612-7415 |
Conference
ID: |
13740164 |
*Replay available through November 14, 2023
About BioXcel Therapeutics, Inc.BioXcel
Therapeutics, Inc. is a biopharmaceutical company utilizing
artificial intelligence approaches to develop transformative
medicines in neuroscience and immuno-oncology. The Company’s drug
re-innovation approach leverages existing approved drugs and/or
clinically validated product candidates together with big data and
proprietary machine learning algorithms to identify new therapeutic
indications. The Company’s commercial product, IGALMI™ (developed
as BXCL501), is a proprietary, sublingual film formulation of
dexmedetomidine approved for the acute treatment of agitation
associated with schizophrenia or bipolar I or II disorder in
adults. The safety and effectiveness of IGALMI have not been
established beyond 24 hours from the first dose. For more
information, please visit igalmi.com and also see the
IGALMI full Prescribing Information. BXCL501 is under
evaluation for at-home use for the acute treatment of agitation in
bipolar and schizophrenia patients, for acute treatment of
agitation associated with Alzheimer’s disease, and as an adjunctive
treatment for major depressive disorder. The safety and efficacy of
BXCL501 for these uses have not been established. The Company is
also developing BXCL502 as a potential therapy for chronic
agitation in dementia. Under its subsidiary, OnkosXcel
Therapeutics, the Company is developing BXCL701, an
investigational, oral systemic innate immune activator for the
treatment of aggressive forms of prostate cancer and other solid
and liquid tumors. The safety and efficacy of BXCL502 and BXCL701
have not been established. For more information, please
visit bioxceltherapeutics.com.
Forward-Looking Statements This press release
includes “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. We intend such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements
contained in this press release other than statements of historical
fact should be considered forward-looking statements, including,
without limitation, the date and time of the Company’s second
quarter 2023 financial results call. When used herein, words
including “anticipate,” “believe,” “can,” “continue,” “could,”
“designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,”
“may,” “might,” “plan,” “possible,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar
expressions are intended to identify forward-looking statements,
though not all forward-looking statements use these words or
expressions. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon the
Company’s current expectations and various assumptions. The Company
believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. The Company may not
realize its expectations, and its beliefs may not prove correct.
Actual results could differ materially from those described or
implied by such forward-looking statements as a result of various
important factors, including, without limitation, the important
factors discussed under the caption “Risk Factors” in its Quarterly
Report on Form 10-Q for the quarterly period ended March 31, 2023,
as such factors may be updated from time to time in its other
filings with the SEC, which are accessible on the SEC’s website at
www.sec.gov. These and other important factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While the Company may elect to
update such forward-looking statements at some point in the future,
except as required by law, it disclaims any obligation to do so,
even if subsequent events cause our views to change. These
forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date of this press release.
Contact Information
Corporate
BioXcel TherapeuticsErik
Kopp1.203.494.7062ekopp@bioxceltherapeutics.com
Investor Relations
BioXcel TherapeuticsBrennan
Doyle1.475.355.8462bdoyle@bioxceltherapeutics.com
Media
Russo PartnersDavid Schull or Scott
Stachowiak1.858.717.2310David.schull@russopartnersllc.comScott.stachowiak@russopartnersllc.com
Source: BioXcel Therapeutics, Inc.
BioXcel Therapeutics (NASDAQ:BTAI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024